Millan M J, Bervoets K, Colpaert F C
Neurobiology Division, Fondax, Groupe de Recherche Servier, Puteaux, France.
J Pharmacol Exp Ther. 1991 Mar;256(3):973-82.
This study pharmacologically characterizes a novel behavioral response as a potential in vivo model of serotonin (5-HT)1A receptor-mediated activity. In rats restrained in horizontal cylinders, the selective 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin HBr (8-OH-DPAT), dose-dependently (0.04-10.0 mg/kg s.c.) elicited spontaneous tail-flicks (STFs). This action was mimicked by other ligands possessing high affinity and high efficacy at 5-HT1A sites: RU 24969 [(5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole], lisuride, (+)-lysergic acid diethylamide and 5-methoxy-N,N-dimethyltryptamine hydrogen oxalate. The response could not be elicited by CGS 12066B [7-trifluormethyl-4-(4-methyl-l-piperazonyl)-pyrrolol- [1-2-a] quinoxaline dimaleate], mCPP 1-(3-chlorophenyl)-piperazine-2-HCl, TFMPPm-trifluromethylphenylpiperazine HCl, MK 212 [6-chloro-2-(l-piperzinyl)pyrazine], quipazine and DOI (+-)-2,5-dimethoxy-4-iodophenyl-2-aminopropane HCl, which act in vivo as agonists at 5-HT1B, 5-HT1C and/or 5-HT2 receptors, or by the 5-HT3 agonist, 2-methyl-5-HT. p-chloroamphetamine, which releases endogenous 5-HT, also evoked STFs; in contrast, d-amphetamine, a preferential releaser of catecholamines, was inactive, as were agonists and antagonists at alpha-1, alpha-2, beta-1, beta-2, dopamine D1 and D2 sites. 8-OH-DPAT-elicited STFs were blocked by the 5-HT1/2 antagonist, methiothepin, but not by the 5-HT1C/5-HT2 antagonists, mianserin, ritanserin and ICI 169,369 [2-(2-dimethylaminoetheylthio)-3-phenylquinoline] nor by the 5-HT3 antagonists, GR 38032F [(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-l-yl)methyl]-4H- carbazol-4-one HCl], ICS 205,930 [(3 alpha-tropanyl)-1H-indol-3-carboxylic acid ester] and MDL 72222 [(1 alpha H, 3 alpha, 5 alpha H)-tripan-3-yl-3,5- dichlorobenzoate]. beta-Blockers with 5-HT1A affinity i.e., (-)-alprenolol, (+/-)-isamoltane and, stereoselectivity, (-)-but not (+)-pindolol, blocked the action of 8-OH-DPAT. Spiperone and spiroxatrine, D2 antagonists with high 5-HT1A affinity, also inhibited 8-OH-DPAT-induced STFs. Selective beta-blockers and D2 antagonists with low 5-HT1A affinity were inactive. 5-HT1A partial agonists, the pyrimidinylpiperazines, buspirone, gepirone and ipsapirone, the halogenated phenylpiperazine, LY 165,163 [1-(2-(4-aminophenyl) ethyl-4-(3-trifluoromethylphenyl)-piperazine], and the benzodioxane, MDL 72832 [8-(4-(1,4-benzodioxan-2-yl-methylamino)-butyl-8-azaspiro-(4 ,5)-decane- 7,9-dione] did not elicit STFs and antagonized the effect of 8-OH-DPAT.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究从药理学角度对一种新的行为反应进行了表征,将其作为5-羟色胺(5-HT)1A受体介导活性的潜在体内模型。在水平圆筒中受束缚的大鼠身上,选择性5-HT1A激动剂8-羟基-2-(二正丙基氨基)四氢萘溴化氢(8-OH-DPAT),以剂量依赖性方式(0.04 - 10.0 mg/kg皮下注射)引发自发甩尾(STF)。具有5-HT1A位点高亲和力和高效能的其他配体也能模拟此作用:RU 24969 [(5-甲氧基-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚]、利苏瑞ide、(+)-麦角酸二乙胺和5-甲氧基-N,N-二甲基色胺草酸氢盐。CGS 12066B [7-三氟甲基-4-(4-甲基-1-哌嗪基)-吡咯并[1-2-a]喹喔啉二马来酸盐]、mCPP 1-(3-氯苯基)-哌嗪-2-盐酸盐、TFMPP m-三氟甲基苯基哌嗪盐酸盐、MK 212 [6-氯-2-(1-哌嗪基)吡嗪]、喹哌嗪和DOI(±)-2,5-二甲氧基-4-碘苯基-2-氨基丙烷盐酸盐在体内作为5-HT1B、5-HT1C和/或5-HT2受体的激动剂,以及5-HT3激动剂2-甲基-5-HT,均不能引发该反应。释放内源性5-HT的对氯苯丙胺也能诱发STF;相比之下,优先释放儿茶胺的右旋苯丙胺无活性,α-1、α-2、β-1、β-2、多巴胺D1和D2位点的激动剂和拮抗剂也无活性。8-OH-DPAT诱发的STF被5-HT1/2拮抗剂甲硫哒嗪阻断,但未被5-HT1C/5-HT2拮抗剂米安色林、利坦色林和ICI 169,369 [2-(2-二甲基氨基乙基硫基)-3-苯基喹啉]阻断,也未被5-HT3拮抗剂GR 38032F [(1,2,3,9-四氢-9-甲基-3-[(2-甲基-1H-咪唑-1-基)甲基]-4H-咔唑-4-酮盐酸盐]、ICS 205,930 [(3α-托烷基)-1H-吲哚-3-羧酸酯]和MDL 72222 [(1αH,3α,5αH)-曲潘-3-基-3,5-二氯苯甲酸酯]阻断。具有5-HT1A亲和力的β-阻滞剂,即(-)-阿普洛尔、(±)-异莫他ane,以及具有立体选择性的(-)-而非(+)-吲哚洛尔,可阻断8-OH-DPAT的作用。具有高5-HT1A亲和力的D2拮抗剂螺哌隆和螺沙群也能抑制8-OH-DPAT诱发的STF。具有低5-HT1A亲和力的选择性β-阻滞剂和D2拮抗剂无活性。5-HT1A部分激动剂,嘧啶基哌嗪类、丁螺环酮、吉哌隆和伊沙匹隆,卤代苯基哌嗪LY 165,163 [1-(2-(4-氨基苯基)乙基-4-(3-三氟甲基苯基)-哌嗪],以及苯并二氧六环MDL 72832 [8-(4-(1,4-苯并二氧六环-2-基甲基氨基)-丁基-8-氮杂螺[4,5]癸烷-7,9-二酮]不会引发STF,并能拮抗8-OH-DPAT的作用。(摘要截选至400字)